Literature DB >> 7283413

Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

M C Thirumoorthi, A S Dajani, C V Vincent, M J Maurer.   

Abstract

We used cefamandole in the initial treatment of 34 children (10 months to 15 years of age) with suspected bone, joint, or soft tissue infections. The minimal inhibitory concentration of organisms encountered ranged between 0.015 and 2 microgram/ml. At 1 h after intravenous infusion of 25 mg/kg, the mean serum level of cefamandole was 26.2 microgram/ml (range, 8.9 to 47.5 microgram/ml), and at 3 h the level was 1.8 microgram/ml (range, 0.6 to 4.4 microgram/ml), which is above the minimal inhibitory concentration for most of the organisms encountered. However, when the drug was given intravenously every 6 h, the mean level after a 37-mg/kg dose was 0.9 microgram/ml (range, less than 0.5 to 1.9 microgram/ml) at 4 h and, by extrapolation, would have fallen below 0.1 microgram/ml at 6 h. The mean serum half-life was 34 min. Cefamandole appeared to diffuse well into synovial fluid, with joint fluid levels between 5 and 40 microgram/ml. The drug was tolerated well. Cefamandole appears to be a reasonable alternative in the initial treatment of skeletal infections in children, but need to be administered every 4 h to maintain suprainhibitory serum levels between doses.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7283413      PMCID: PMC181625          DOI: 10.1128/AAC.20.1.21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.

Authors:  R L Perkins; R J Fass; J F Warner; R B Prior; T M File; R R Tight; W G Gardner; D E Ruiz; T G Slama
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

2.  Clinical and laboratory evaluation of cefamandole in infants and children.

Authors:  W J Rodriguez; S Ross; W N Khan; R Goldenberg
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

3.  Clindamycin treatment of osteomyelitis and septic arthritis in children.

Authors:  R D Feigin; L K Pickering; D Anderson; R E Keeney; P G Shackleford
Journal:  Pediatrics       Date:  1975-02       Impact factor: 7.124

4.  Antibacterial activity of cefamandole in vitro.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

5.  Cefamandole and cefazolin in the therapy of complicated urinary tract infections.

Authors:  U Hoyme; P O Madsen
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

6.  Clinical experience with cefamandole for treatment of serious bone and joint infections.

Authors:  L R Levine; E McCain
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

7.  Cefamandole in treatment of peritonitis.

Authors:  H H Stone; B S Guest; C E Geheber; L D Kolb
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

8.  Microbioassay of antimicrobial agents.

Authors:  H J Simon; E J Yin
Journal:  Appl Microbiol       Date:  1970-04

9.  Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis.

Authors:  T R Tetzlaff; G H McCracken; J D Nelson
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

10.  Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin.

Authors:  S Eykyn; C Jenkins; A King; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

View more
  2 in total

1.  Newer antibiotics.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1981 Sep-Oct       Impact factor: 1.967

2.  Cephalosporins: recent developments.

Authors:  A Kumar
Journal:  J Natl Med Assoc       Date:  1983-02       Impact factor: 1.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.